Background
The clinical significance of
KRAS codon 12 and 13 mutation tests in the selection of patients with colorectal cancer who might benefit from anti-epidermal growth factor receptor (EGFR) antibodies is well established, and regulatory authorities in Europe, the United States, and Japan have recommended compulsory
KRAS mutation testing before treatment [
1‐
6]. Although conventional
KRAS tests are useful to decrease treatment to nonbeneficiary populations, the efficacy of determining beneficiary populations requires improvement. The response rate to anti-EGFR antibody monotherapy among pretreated patients with tumors harboring
KRAS codons 12 and 13 wild-type is 13%–17% [
1,
2], and that of combination anti-EGFR antibody and cytotoxic agent therapy is 11%–35% [
5,
7]. One explanation for such relatively low efficacy is that molecular alterations other than
KRAS codon 12 and 13 mutations might confer resistance to anti-EGFR antibody therapies. Recent retrospective studies have revealed that mutations in
KRAS codons 61 and 146,
BRAF,
NRAS, and
PIK3CA are also related to resistance to anti-EGFR antibodies [
8‐
13].
Several issues should also be considered to establish the clinical utility of expanded genome biomarker tests for anti-EGFR antibodies. First, information about the relation between mutation status and efficacy of treatment, especially among Asian populations, is still limited. Second, efficacious quality-controlled in vitro diagnostic kits and systems suitable for multiple genome biomarker detection are needed.
In Japan, a
KRAS mutation assay kit based on the ARMS–scorpion method that detects seven frequently observed mutations in
KRAS codons 12 and 13 (TheraScreen® K-RAS Mutation Kit; QIAGEN) was first approved for
in vitro diagnostic use, and a kit using Luminex (xMAP) assay (MEBGEN KRAS Mutation Detection Kit, MBL) followed [
14,
15]. We recently developed another Luminex-based research-use kit, GENOSEARCH Mu-PACK, which simultaneously detects 36 mutations in
KRAS codons 61 and 146,
BRAF,
NRAS, and
PIK3CA. In addition to the hitherto approved
KRAS codon 12 and 13 mutation kit, the multiplex kit identifies mutations by a single tube reaction using 50 ng of template DNA from formalin-fixed paraffin-embedded (FFPE) specimens.
In this study, we examined the feasibility and robustness of this multiplex kit using routine clinical samples collected from multiple hospitals. Meanwhile, we collected precise clinical data for these cases and retrospectively analyzed the relation of the mutation profiles of expanded markers to clinical outcomes following cetuximab therapy.
Methods
Patients
We screened and selected clinical and pathological data from consecutive patients who were administered either cetuximab monotherapy or cetuximab plus irinotecan between July 2008 and April 2010.
Patients who met all of the following inclusion criteria were retrospectively included in the analyses: (1) age ≥20 years; (2) histologically confirmed adenocarcinoma of the colon or rectum; (3) presence of unresectable metastatic disease; (4) baseline computed tomography (CT) performed within 28 days of initial cetuximab administration; (5) initial CT evaluation performed within 3 months of initial cetuximab administration; (6) previously documented as refractory or intolerant to fluoropyrimidines, oxaliplatin, and irinotecan; (7) Eastern Cooperative Oncology Group performance status score ≤2; and (8) adequate hematological, hepatic, and renal functions.
In the monotherapy regimen, cetuximab was administered at an initial dose of 400 mg/m2 followed by weekly infusions of 250 mg/m2. In the cetuximab plus irinotecan regimen, cetuximab was administered at the same dose as for monotherapy and followed by biweekly infusions of 150 mg/m2 irinotecan, as per the manufacturer’s instructions for irinotecan in Japan.
The study was conducted with the approval of the National Cancer Center Institutional Review Board, Cancer Institute Hospital of Japanese Foundation for Cancer Research Review Board, National Hospital Organization Shikoku Cancer Center Review Board, Shizuoka Cancer Center Review Board, Saitama Cancer Center Review Board, Hokkaido University Review Board, and the Ethics Committee of the University of Toyama. Written informed consent was obtained from as much patients who were alive as possible. For the deceased patients and their relatives, we also disclosed the study design at the website of National Cancer Center and gave them chances to express their wills in accordance with Epidemiological Study Guideline of Ministry of Health, Labour and Welfare in Japan.
Tissue samples and DNA extraction
Genomic DNA was obtained from primary and metastatic colorectal cancer tissues of all patients treated with cetuximab. Tissue samples harvested by biopsy or surgical resection at the participating hospitals were collected and sent to the research institution (MBL, Japan). A 2-μm hematoxylin-eosin (HE) slide and a 10-μm unstained slide were obtained from the FFPE tissue blocks; the latter was subsequently sliced into 3–10 sections. Pathological diagnoses were confirmed by a pathologist (Satoshi Fujii), with reference to the 4
th edition of the WHO classification. The tumor area, determined by examining HE slides, was macroscopically dissected. Genomic DNA was isolated as described previously [
16].
Luminex (xMAP) tests
A total of 36 mutations of KRAS codon 61 (Q61K, Q61E, Q61L, Q61P, Q61R, Q61H), KRAS codon 146 (A146T, A146S, A146P, A146E, A146V, A146G), BRAF codon 600 (V600E), NRAS codon 12 (G12S, G12C, G12R, G12D, G12V, G12A), codon 13 (G13S, G13C, G13R, G13D, G13V, G13A), codon 61 (Q61K, Q61E, Q61L, Q61P, Q61R, Q61H), PIK3CA exon 9 codon 542 (E542K), codon 545 (E545K), codon 546 (E546K), and exon 20 codon 1047 (H1047R, H1047L) were analyzed using Luminex (xMAP) technology (GENOSEARCH Mu-PACK, MBL, Japan).
First, 50 ng of template DNA collected from FFPE tissue samples was amplified by polymerase chain reaction (PCR) using a biotin-labeled primer. Thereafter, the PCR products and fluorescent Luminex beads (oligonucleotide probes complementary to wild and mutant genes were bound to the beads) were hybridized and labeled with streptavidin–phycoerythrin. Subsequently, the products were processed by Luminex assay and the collected data analyzed using UniMAG software (MBL, Japan). The procedure time was approximately 4.5 h.
We also used the Luminex assay kit (MEBGEN KRAS Mutation Detection Kit, MBL, Japan) currently approved for clinical use by the Ministry of Health, Labour and Welfare of Japan [
16] to detect
KRAS codon 12 and 13 mutations.
Direct sequencing methods
In addition, to confirm the mutations detected by the Luminex assays, the same mutations of KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA were analyzed by direct sequencing. A total of 700 ng of template DNA was used for these PCR reactions and the PCR products were directly sequenced with the same primers used for PCR. A BigDye Terminator v3.1 Cycle Sequencing Kit and an ABI PRISM 3730xl DNA Analyzer (Life Technologies) were used. Analyses of DNA sequences were performed using Sequencher (GeneCodes).
Statistical analysis
Response rates (RRs) and disease control rates (DCRs) (including complete or partial response and stable disease) were evaluated as per the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Progression-free survival (PFS) was defined as the time from initial administration of a cetuximab-containing regimen to either the first objective evidence of disease progression or death from any cause. Overall survival (OS) was defined as the time from initial administration of a cetuximab-containing regimen to death from any cause. RRs, DCRs, PFS, and OS of all patients were re-evaluated by the principal investigators at each institution. The relative dose intensity was defined as the ratio of the actual dose administered to the planned dose.
Fisher’s exact test and the Kruskal–Wallis test were used to compare patient characteristics, relative dose intensity, and treatment response. PFS and OS data were plotted as Kaplan–Meier curves, and differences among the groups according to KRAS, BRAF, NRAS, and PIK3CA gene status were compared using the log-rank test and hazard ratio calculated from a Cox regression model with a single covariate. All analyses were performed by a biostatistician (Takeharu Yamanaka), using IBM SPSS® Statistics 21 package software (SPSS Inc., Tokyo, Japan).
Discussion
This study is the first to verify the relevance of the mutation status of
KRAS codons 61 and 146,
BRAF,
NRAS, and
PIK3CAto the clinical efficacy of anti-EGFR antibody therapy among Asian patients. As reported in a pooled analysis from a European population, patients with the aforementioned less-frequent mutations exhibited statistically significant worse outcomes equivalent to those of
KRAS codon 12 and 13 mutants [
8]. Though systemically analyzed studies have not been reported since the first European analysis, our results strongly support the usefulness of the expanded pretreatment test for anti-EGFR therapies.
Because our aim was to compare the outcomes of
KRAS codon 12 and 13 mutant cases with those characterized by other mutations, clinical data and FFPE specimens of the patients treated with cetuximab-containing regimens at seven Japanese cancer centers from July 2008 to April 2010 were collected. At that time, the Japanese authorities did not require pretreatment
KRAS tests, and patients with
KRAS codon 12 and 13 mutations were eventually treated with cetuximab. However, the proportion of patients with
KRAS codon 12 or 13 mutant tumors in this study (25.6%) was slightly lower than that in previous reports of Western and Asian study populations [
18], supposedly because several participating institutions had established lab-based tests and used the data for selecting nonbeneficiary populations. Among
KRAS codon 12 and 13 wild-type cases, the proportion with mutations of overall tested genes (12/61, 19.7%) was similar to that of previous reports, suggesting that such expanded testing would be equally useful in Western and Asian countries.
Because the potential usefulness of multiplex mutation analyses is demonstrated, the development of robust
in vitro diagnostic systems is needed for clinical application. The application of multiplex mutation detection systems in colorectal cancer specimens has been reported. Lurkin I. et al. reported the validity of multiplex assays using a SNaPshot® Multiplex kit (Life Technologies), which detects 22 mutations in
KRAS,
BRAF,
NRAS, and
PIK3CA[
19]. Here we evaluated a quality-controlled kit detecting 36 mutations of
KRAS codons 61 and 146,
BRAF,
NRAS, and
PIK3CA using Luminex (xMAP) technology. Data obtained by this kit were fully concordant with those by conventional direct sequencing, regardless of any variation in fixation methods between participating institutes (unpublished data).
This kit has several advantages with regard to its development for routine clinical use. It is manufactured under the same quality as the hitherto approved
in vitro diagnostic kit detecting mutations in
KRAS codons 12 and 13. Design of the hands-on operations is simple and easy; detection of the 36 mutations is performed in a single reaction of multiplex PCR followed by Luminex bead assay, with an overall hands-on time of 4.5 h. In addition, the requirement for template DNA is as low as 50 ng. We collected a median of 370 ng (range: 154–889) DNA per 10-μm biopsy slice in this study, which is sufficiently large to perform the test and to reserve backup DNA. Meanwhile, the ARMS–Scorpion assay, another approved
in vitro diagnostic kit, requires larger amounts of template DNA. The currently approved
KRAS codons 12 and 13 kit consists of 8 (1 control and 7 mutations) PCR reactions. A total of 80–160 ng of template DNA (10–20 ng for each PCR reaction) are needed to examine a sample [
20], and it would be difficult to expand the PCR reactions because of the limitation of template DNA.
It has been estimated that approximately 10%–20% of all patients with colorectal cancer have either
KRAS codon 61,
KRAS codon 146,
BRAF,
NRAS, or
PIK3CA gene mutations, suggesting that approximately 60,000–120,000 patients (10%–20% of the 600,000 who die annually from colorectal cancer) worldwide could be screened by this expanded mutation test. Furthermore, because the usefulness of regular administration of aspirin for patients with mutated
PIK3CA colorectal cancer and the possibility of combining EGFR and BRAF inhibitors for patients with mutated
BRAF colorectal cancer have been reported, detection of those mutations could become of greater importance in many ways [
21,
22]. Once further studies with larger sample sizes and a range of clinical samples provide evidence of its clinical utility, this technique might advance the precision of colorectal cancer treatment.
Conclusions
Our newly developed multiplex kit is practical and feasible for investigating various types of FFPE samples. Moreover, mutations in KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA detected in Asian patients were not predictive of clinical benefits from cetuximab treatment, similar to the result obtained in European studies.
Funding
This study was supported by a Grant-in-Aid for Cancer Research (21 S4-5) from the Ministry of Health, Labour and Welfare of Japan.
Research group members
Hideaki Bando, Takayuki Yoshino, Katsuya Tsuchihara, Satoshi Fujii, Kohei Shitara, Takeharu Yamanaka, and Atsushi Ohtsu (National Cancer Center Hospital East); Satoshi Yuki and Takahide Sasaki (Hokkaido University); Eiji Shinozaki (Cancer Institute Hospital of Japanese Foundation for Cancer Research); Tomohiro Nishina (Shikoku Cancer Center); Kensei Yamaguchi, Shigenori Kadowaki, and Masako Asayama (Saitama Cancer Center); Kentaro Yamazaki (Shizuoka Cancer Center) and Shinya Kajiura (University of Toyama).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TY and KT conceived the study design. HB carried out the majority of molecular genetic studies and analyses of the clinical data. ES, TN, KY, KY, SY, and SK provided clinical data and helped collect tumor tissues. SF carried out the pathological diagnoses. TY statistically analyzed the clinical data. AO coordinated the study and helped to draft the manuscript. All authors have read and approved the final manuscript.